FDA GRANTS PAR FINAL APPROVAL FOR GENERIC PARNATE

The FDA has approved Par Pharmaceutical's generic equivalent of GlaxoSmithKline's depression drug Parnate, the drugmaker said. Par will market the drug in 10-mg tablets.

Parnate was one of 11 antidepressants given a black box warning in January 2005 after the FDA approved labeling revisions to antidepressants to describe the increased risk of suicidal behavior in children and adolescents who take the drugs.